Depression Treatment: Preventive Strategies in Depression: Gathering Evidence for Risk Factors and Potential Interventions.

Preventive strategies in depression: gathering evidence for risk factors and potential interventions.

Filed under: Depression Treatment

Br J Psychiatry. 2012 Nov; 201: 339-41
Berk M, Jacka F

This editorial critiques the recent literature concerning both vitamin D deficiency in major depression and supplementation as a treatment strategy, and contextualises it within a broader approach to the prevention of depression, based on the recent evidence for lifestyle as a risk factor for depression and anxiety.
HubMed – depression

 

Depression and cardiovascular disease: the end of simple models.

Filed under: Depression Treatment

Br J Psychiatry. 2012 Nov; 201: 337-8
de Jonge P, Roest AM

In this editorial, we propose that the association between depression and cardiovascular disease may be conceptualised as a continuous, bidirectional process that originates in youth. The paper byÅ(berg) and colleagues in this issue adds to this literature showing that low cardiovascular fitness at adolescence increases the risk of future depression.
HubMed – depression

 

In vivo and in vitro characterization of naltrindole-derived ligands at the ?-opioid receptor.

Filed under: Depression Treatment

J Psychopharmacol. 2012 Oct 31;
Casal-Dominguez JJ, Clark M, Traynor JR, Husbands SM, Bailey SJ

Accumulating evidence supports a role for ?-opioid receptor antagonists in the treatment of mood disorders. Standard ?-antagonists have an unusual pharmacodynamic action, with a single injection blocking receptor signaling for several weeks. Here, we have characterized the ?-selective properties of two ligands, 5′-(2-aminomethyl) naltrindole (5′-AMN) and N-((Naltrindol-5-yl) methyl) pentanimidamide (5′-MABN), to identify whether modifications of the naltrindole side chain produces short-acting ?-antagonists. Opioid receptor binding affinity and activity were assessed using [(3)H]-diprenorphine binding, guanosine-5′-O-(3-[35S]-thio) triphosphate ([(35)S]-GTP?S) binding and isolated guinea-pig ileum. Pharmacodynamic profiles of 5′-AMN and 5′-MABN (1-10 mg/kg) were investigated using the tail-withdrawal assay and diuresis. Efficacy was also determined in depression- and anxiety-related behavioral paradigms in CD-1 mice. Both 5′-AMN and 5′-MABN had high affinity for ?-receptors (K(i) 1.36±0.98 and 0.27±0.08, respectively) and were revealed as potent ?-antagonists (pA(2) 7.43 and 8.18, respectively) and ?-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum. Contrary to our hypothesis, in vivo, 5′-AMN and 5′-MABN displayed long-lasting antagonist effects in mice, reducing the antinociceptive actions of U50,488 (10 mg/kg) at 28 and 21 days post-injection, respectively. Interestingly, while 5′-AMN and 5′-MABN were not ?-selective, both compounds did show significant antidepressant- and anxiolytic-like effects at 7-14 days post-injection in mice.
HubMed – depression

 

Treatment Plans and Interventions for Depression and Anxiety Disorders

$7.37
End Date: Wednesday Oct-16-2019 11:08:59 PDT
Buy It Now for only: $7.37
Buy It Now | Add to watch list

 

Treatment for Chronic Depression : Cognitive Behavioral Analysis System of Psych
$7.17
End Date: Sunday Oct-6-2019 7:36:31 PDT
Buy It Now for only: $7.17
Buy It Now | Add to watch list

 

Depression : Treatment Strategies and Management
$6.46
End Date: Saturday Sep-28-2019 3:09:15 PDT
Buy It Now for only: $6.46
Buy It Now | Add to watch list

 

Find More Depression Treatment Information…